Akcea Therapeutics, Inc. (AKCA) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research cut shares of Akcea Therapeutics, Inc. (NASDAQ:AKCA) from a hold rating to a sell rating in a report released on Tuesday.

According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research analysts have also recently issued reports on AKCA. BMO Capital Markets began coverage on shares of Akcea Therapeutics in a report on Tuesday, August 8th. They issued an outperform rating and a $25.00 target price for the company. Stifel Nicolaus started coverage on shares of Akcea Therapeutics in a report on Tuesday, August 8th. They issued a buy rating and a $19.00 target price for the company. Cowen and Company started coverage on shares of Akcea Therapeutics in a research note on Tuesday, August 8th. They set an outperform rating for the company. Finally, Wells Fargo & Company started coverage on shares of Akcea Therapeutics in a research note on Tuesday, August 8th. They set an outperform rating and a $27.00 price objective for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $23.67.

Shares of Akcea Therapeutics (AKCA) opened at 24.05 on Tuesday. Akcea Therapeutics has a 1-year low of $8.10 and a 1-year high of $31.23. The stock’s market capitalization is $1.54 billion. The firm’s 50-day moving average price is $23.96 and its 200 day moving average price is $17.88.

TRADEMARK VIOLATION WARNING: “Akcea Therapeutics, Inc. (AKCA) Downgraded to “Sell” at Zacks Investment Research” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/10/11/akcea-therapeutics-inc-akca-downgraded-to-sell-at-zacks-investment-research.html.

In other Akcea Therapeutics news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was acquired at an average cost of $8.00 per share, with a total value of $25,000,000.00. Following the purchase, the insider now directly owns 28,884,540 shares in the company, valued at approximately $231,076,320. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

About Akcea Therapeutics

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients

According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research analysts have also recently issued reports on AKCA. BMO Capital Markets began coverage on shares of Akcea Therapeutics in a report on Tuesday, August 8th. They issued an outperform rating and a $25.00 target price for the company. Stifel Nicolaus started coverage on shares of Akcea Therapeutics in a report on Tuesday, August 8th. They issued a buy rating and a $19.00 target price for the company. Cowen and Company started coverage on shares of Akcea Therapeutics in a research note on Tuesday, August 8th. They set an outperform rating for the company. Finally, Wells Fargo & Company started coverage on shares of Akcea Therapeutics in a research note on Tuesday, August 8th. They set an outperform rating and a $27.00 price objective for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $23.67.

Shares of Akcea Therapeutics (AKCA) opened at 24.05 on Tuesday. Akcea Therapeutics has a 1-year low of $8.10 and a 1-year high of $31.23. The stock’s market capitalization is $1.54 billion. The firm’s 50-day moving average price is $23.96 and its 200 day moving average price is $17.88.

TRADEMARK VIOLATION WARNING: “Akcea Therapeutics, Inc. (AKCA) Downgraded to “Sell” at Zacks Investment Research” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/10/11/akcea-therapeutics-inc-akca-downgraded-to-sell-at-zacks-investment-research.html.

In other Akcea Therapeutics news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was acquired at an average cost of $8.00 per share, with a total value of $25,000,000.00. Following the purchase, the insider now directly owns 28,884,540 shares in the company, valued at approximately $231,076,320. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

About Akcea Therapeutics

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply